UNIGE document Scientific Article - Meta-analysis
previous document  unige:25368  next document
add to browser collection

Do RANKL inhibitors (denosumab) affect inflammation and immunity?

Published in Osteoporosis International. 2011, vol. 22, no. 2, p. 435-46
Abstract Receptor activator of nuclear factor kappa B ligand (RANKL) and its natural antagonist, osteoprotegerin (OPG), are, respectively, an indispensable factor and a potent inhibitor for osteoclast differentiation, activity, and survival. The development of a human monoclonal antibody to RANKL, denosumab, constitutes a novel approach to prevent fragility fractures in osteoporosis, skeletal complications of malignancy, and potentially bone erosions in rheumatoid arthritis (RA). In addition to being expressed by osteoblasts, RANKL is abundantly produced by activated T cells, and synoviocytes in RA, whereas its receptor, RANK, is also expressed by monocytes/macrophages and dendritic cells. However, in preclinical and clinical studies of RA-including patients with some degree of immunosuppression-RANKL inhibitors did not significantly alter inflammatory processes. RANKL, RANK, and OPG deficiency in murine models highlights the important role of this pathway in the development and maturation of the immune system in rodents, including functions of T and/or B cells, whereas OPG overexpression in mice and rats seems innocuous with regard to immunity. In contrast, loss-of-function mutations in humans have more limited effects on immune cells. In clinical studies, the overall rate of infections, cancer, and death was similar with denosumab and placebo. Nevertheless, the risk of severe infections and cancer in some specific tissues remains to be carefully scrutinized.
Keywords AnimalsAntibodies, Monoclonal/adverse effects/pharmacologyArthritis, Rheumatoid/physiopathologyB-Lymphocytes/metabolismBone Resorption/physiopathologyFemaleHumansInfection/chemically inducedMiceNeoplasms/chemically inducedOsteoblasts/metabolismOsteoclasts/metabolismOsteoporosis/physiopathologyOsteoprotegerin/pharmacologyRANK Ligand/adverse effects/pharmacologyRatsReceptor Activator of Nuclear Factor-kappa B/antagonists & inhibitorsT-Lymphocytes/metabolismTumor Necrosis Factor-alpha/antagonists & inhibitors
PMID: 20571772
Full text
Article (Published version) (322 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research groups Transplantation Immunologie et Osteoimmunologie (561)
Génétique des Ostéoporoses (544)
(ISO format)
FERRARI-LACRAZ, Sylvie, FERRARI, Serge Livio. Do RANKL inhibitors (denosumab) affect inflammation and immunity?. In: Osteoporosis International, 2011, vol. 22, n° 2, p. 435-46. https://archive-ouverte.unige.ch/unige:25368

151 hits

0 download


Deposited on : 2013-01-10

Export document
Format :
Citation style :